Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Stock Quote Today & Recent News
Adynxx Inc (EM)
ADYX
Healthcare
Biotechnology
Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a...
pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.
see more
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Current News
(EXPM:ADYX)
Adynxx Reports Third Quarter 2019 Financial Results
GlobeNewswire November 14, 2019
Healthcare
Adynxx Receives NIH HEAL Initiative Funding Award for Development of Second Non-Opioid Pain Therapeutic
GlobeNewswire October 2, 2019
Healthcare
Adynxx Reports Second Quarter 2019 Financial Results
GlobeNewswire August 14, 2019
Healthcare
Adynxx Adds Gregory J. Flesher to Board of Directors, Completes Up-listing to OTCQB Market
GlobeNewswire July 22, 2019
Healthcare
Adynxx Stock to Move to OTC Market Following Receipt of Nasdaq Delisting Notice
GlobeNewswire June 12, 2019
Healthcare
Adynxx Announces Payment Date of Special Cash Dividend Previously Announced by Alliqua BioMedical
GlobeNewswire May 10, 2019
Healthcare
Adynxx, Inc. Receives Nasdaq Notice of Delisting or Failure to Satisfy an Initial Listing Rule or Standard
GlobeNewswire May 9, 2019
Healthcare
Adynxx Completes Merger with Alliqua BioMedical, Adds Pierre Legault and Matt Ruth to Board of Directors
GlobeNewswire May 6, 2019
Healthcare
Alliqua BioMedical Declares Contingent Special Dividend of $1.05 per Share and Announces Record Date for the Contingent Special Dividend and the Spin-Off of Contract Manufacturing Business
GlobeNewswire April 11, 2019
Healthcare
View More News ››
Opinion & Analysis
(EXPM:ADYX)
No current opinion is available.
View More Opinion ››
Bullboard Posts
(EXPM:ADYX)
ALQA: Massive Explosion Within Days?
Stock analysis ALQA: Massive Explosion Within Days?
Muusmann
- March 22, 2019
NEWS
Alliqua, Inc. Announces Preparation of IND for PHN PatchNEW YORK, May 03, 2011 (BUSINESS WIRE) -- Alliqua, Inc. (OTCBB: ALQA) (FWB:...
golf4you1
- May 3, 2011
View more Bullboard ››
Featured News Links
Building Momentum in One of the World's Most Prospective Copper Regions
Sorrento Resources Provides Update on Exploration on Rodgers Cove Project, Newfoundland
A tungsten producer and developer in Portugal, South Korea & Spain on track to become a top supplier
DiagnosTear Announces Clinical Study to Advance Analytical Validation & FDA Submission Pathway of TeaRx(TM)
A Company Focused on Developing Functional Healthier “Better For You” Foods
Alvopetro Energy Ltd.
Alvopetro Energy Ltd. engages in the acquisition, exploration, development, and production of hydrocarbons in Brazil and ...
View More »